Ceribell

company

About

Ceribell focuses on making electroencephalography accessible, efficient, and cost-effective.

  • 51 - 100

Details

Last Funding Type
Debt Financing
Last Funding Money Raised
$20M
Industries
Biotechnology,Health Care,Health Diagnostics,Medical Device
Founded date
Jan 1, 2014
Number Of Employee
51 - 100
Operating Status
Active

Ceribell focuses on making electroencephalography (EEG) widely accessible, more efficient, and more cost-effective.

The company creates and validates an FDA cleared instant EEG system that does not require an EEG technologist or specialist interpreter, which allows for faster results and clinical decision-making. The Ceribell EEG System can be set up by any healthcare provider in 6 minutes and offers a proprietary Brain Stethoscope function that dramatically simplifies interpretation of EEG results by converting brainwaves to sound so seizures can be detected by listening. Earlier diagnosis and focused treatment for patients with seizures, including non-convulsive seizures that can only be diagnosed with EEG, can significantly lower mortality, secondary brain injury, length of stay, and risk of complications.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$55M
Ceribell has raised a total of $55M in funding over 2 rounds. Their latest funding was raised on May 1, 2020 from a Debt Financing round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
May 1, 2020 Debt Financing $20M 1 Horizon Technology Finance Detail
Sep 25, 2018 Series B $35M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
2
Ceribell is funded by 2 investors. Horizon Technology Finance and UCB are the most recent investors.
Investor Name Lead Investor Funding Round
Horizon Technology Finance Yes Debt Financing
UCB Series B